

Cambrian


James Peyer, PhD

Founder & CEO

Creating Longevity Drugs at Scale

2021-11-17

Someone dies of a disease of aging nearly every second of every day



- **4,600** people die every hour
- **112,000** people every day
- **41 million** people every year

These are more than double the total worldwide deaths from all other causes combined.

Today we expect to live into our late first century

02



Healthy first half

"Youth is a wonderful thing. What a crime to waste it on children."

-George Bernard Shaw



Declining second half

"All diseases run into one, old age."

-Ralph Waldo Emerson

Our growing understanding of the biology of aging is opening the door to a revolutionary change

03

Scientists have discovered more than 75 independent biomedical interventions to extend healthy lifespan in mammals.

Humans are next.



Waiting for people to get sick and **ONLY THEN** trying to cure them has not worked for age-related diseases

Alzheimer's



Healthy brain



Alzheimer's
Disease brain


200+

Failed clinical trials


x2

Increase since 2000

Heart Disease



Healthy heart



Infarcted heart


#1

Cause of death


0

Drugs heal the heart

Cancer



Healthy tissue



Malignant
tumour

2 mo


Average delay in death

\$170B

Spent per year

Age-related diseases are caused by buildup of decades of damage

As we age, our risk of getting the diseases of aging rises exponentially.



Cambrian’s medicines aim to extend healthspan, keeping people healthy for many extra years



Cambrian’s strategy uses established regulatory frameworks to lay the foundation for healthspan-extending medicines

Building valuable biotechs under our umbrella while laying the foundation for clinical trials in aging



More than 75 drugs and gene therapies extend healthy lifespan of mice

Cambrian strategy

Develop medicines which repair the damage caused by aging, though initial trials are in FDA-recognized diseases


Cambrian trials are designed to validate biomarkers that can be used to run trials for multi-morbidity risk (i.e. aging)

Create an enduring R&D company that captures the market shift from reactive to preemptive therapies

Cambrian

We are a distributed biotech company developing a wide pipeline of new medicines targeting the causes of aging and age-related diseases.

We work with top scientists that have made fundamental breakthroughs and pair them with our in-house R&D, Operations, and Venture teams to bring those breakthroughs to patients.




Cambrian develops novel therapeutics targeting the causes of age-related decline

Each of Cambrian's therapies target genes, pathways, or processes that:

- 1 Change for the worse with age
- 2 Accelerate onset of aging diseases when amplified
- 3 Slow or reverse age-related decline when removed

Causes of Aging – Prioritized Cambrian Opportunities



Molecular alterations

Accumulate within our cells as we age, laying the groundwork for disease


- Short telomeres
- Disrupted proteostasis
- DNA damage
- Loss of epigenetic information



Cellular dysfunction

Results from accumulated damage, preventing our cells from functioning optimally

- Loss of tissue stem cells
- Buildup of damaged cells
- Over-active cell growth signals
- Mitochondrial damage



Tissue degeneration


Occurs as lost or damaged cellular structures are no longer replaced, and systemic signals make the body less resilient

- Stiff extracellular matrices
- Buildup of extracellular aggregates
- Changes in hormone signaling
- Non-regenerating adult tissues
- Chronic inflammation

Cambrian Pipeline Snapshot

14 majority owned and Cambrian operated therapies in development

On track to reach 18 programs by EOY 2021



Scientists and Executives Across Cambrian and our PipeCos Create an Unmatched Team

Ventures



J. Peyer
CEO



F. Ahmad
Venture Director



L. Friedman
Venture Director



E. Sarnoski
Venture Director



M. Yurkovich
Venture Director



R. Gokarn
Geroscience
Strategy



D. Robinton
DIR Women's
Health, CEO Oviva



V. Sriram
DIR, Head of
Fibrosis Program

Operations



J. Han
COO



M. Kurtz
Director,
People & Culture



A. Feng
Director,
Finance



Y. Li
Director,
Pipeline Operations



B. Mills
Operations
Associate



W. Luo
Operations
Manager



A. Baranowski
Pipeline
Operations Fellow

BD



M. Nuttall
EVP, BD

Research & development



G. Terstappen
EVP,
Drug Discovery



D. Yamashita
EVP, Chemistry



C. O'Brien
Sr. Director, R&D



S. Mazza-Lunn
Sr. Manager, R&D



D. Falk
Co-Founder & CEO,
Vita



P. Andersen
Co-Founder & CSO,
Vita



S. Brooks
SVP, Medical Sciences,
Vita



G. Lee
Scientific Co-Founder,
Vita



K. Strange
Scientific Founder,
Novo



V. Yin
Scientific Founder,
Novo



D. Rudin
Clinical Lead,
Novo



R. Corder
Scientific Founder,
Nugerontix



D. Pépin
Co-Founder,
Oviva



P. Donahoe
Co-Founder,
Oviva



J. Prakash
Founder & CEO,
ScarTec



B. Metselaar
COO,
ScarTec



E. Tzahor
Scientific Founder,
CAM-6019



K. Umansky
Scientific Founder,
CAM-6019



D. Tschumperlin
Scientific Founder,
Elastic



A. Haak
Scientific Founder,
Elastic



M. Griffin
Scientific Founder,
Isterian



D. Rathbone
Scientific Founder,
Isterian



Z. Wang
Scientific Founder,
Isterian



M. Petrascheck
Scientific Founder,
Cyclone



K. Clay
Scientific Founder,
Cyclone



J. Shay
Scientific Founder,
Telos



E. Tedone
Scientific Founder,
Telos



M. Sayed
Scientific Founder,
Telos



D. Huffman
Scientific Founder,
Ascetic



E. Gavathiotis
Scientific Founder,
Ascetic



D. Shechter
Scientific Founder,
Ascetic

Summary: Cambrian's exponential growth has built the foundation for the first longevity pharma company

14

PipeCo Programs and growing

3+

Longevity drugs ready for clinic in 2022

>100

Full time employees across the DisCo



THANK YOU

Cambrian

 @cambrianbio

 @jamespeyer

cambrianbio.com

info@cambrianbio.com